Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

Inovio Pharmaceuticals News (NASDAQ:INO)

Inovio Pharmaceuticals stock quote | Inovio Pharmaceuticals company information | Inovio Pharmaceuticals Stock Chart | Inovio Pharmaceuticals Stock News
DateTimeSource
Headline
03/26/20246:28PMPRNUSINOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine
INOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine PR Newswire PLYMOUTH MEETING, Pa., March 26, 2024 PLYMOUTH MEETING, Pa., March 26, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people... More...>>
03/06/20244:05PMPRNUSINOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
INOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights PR Newswire PLYMOUTH MEETING, Pa., March 6, 2024 Announced substantial progress with lead program, INO-3107, as potential treatment for Recurrent Respiratory Papillomatosis (RRP)Positive data announced from Phase 1/2 trialOrphan... More...>>
03/06/20247:00AMPRNUSGeneos Therapeutics to Present New Clinical Data on GNOS-PV02 at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Geneos Therapeutics to Present New Clinical Data on GNOS-PV02 at the 2024 American Association for Cancer Research (AACR) Annual Meeting PR Newswire PHILADELPHIA, March 6, 2024 PHILADELPHIA, March 6, 2024 /PRNewswire/ -- Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of personalized... More...>>
03/06/20246:02AMIHMARKETNEWSU.S. Stock Futures Gain Ahead of Economic Insights; Oil Prices Climb
U.S. index futures signal a higher opening after two days of declines, with the market focusing on the ADP survey and the Fed’s Beige Book, seeking clues about the future economy and monetary policy. At 05:31 AM, Dow Jones futures (DOWI:DJI) rose 92 points, or 0.24%. S&P 500 futures advanced 0.39%, and Nasdaq-100... More...>>
02/21/20248:00AMPRNUSINOVIO to Report Fourth Quarter and Year-End 2023 Financial Results on March 6, 2024
INOVIO to Report Fourth Quarter and Year-End 2023 Financial Results on March 6, 2024 PR Newswire PLYMOUTH MEETING, Pa., Feb. 21, 2024 PLYMOUTH MEETING, Pa., Feb. 21, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people... More...>>
02/07/202411:46AMPRNUSINOVIO to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
INOVIO to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference PR Newswire PLYMOUTH MEETING, Pa., Feb. 7, 2024 PLYMOUTH MEETING, Pa., Feb. 7, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from... More...>>
02/02/20248:00AMPRNUSINOVIO Reports Inducement Grant Under Inducement Plan
INOVIO Reports Inducement Grant Under Inducement Plan PR Newswire PLYMOUTH MEETING, Pa., Feb. 2, 2024 PLYMOUTH MEETING, Pa., Feb. 2, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer... More...>>
01/23/20248:00AMPRNUSINOVIO Announces Effective Date of 1-for-12 Reverse Stock Split
INOVIO Announces Effective Date of 1-for-12 Reverse Stock Split PR Newswire PLYMOUTH MEETING, Pa., Jan. 23, 2024 PLYMOUTH MEETING, Pa., Jan. 23, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases... More...>>
01/22/20248:00AMPRNUSINOVIO to Participate in Virtual Fireside Chat on the Potential Treatment of Recurrent Respiratory Papillomatosis with Key Opinion Leader
INOVIO to Participate in Virtual Fireside Chat on the Potential Treatment of Recurrent Respiratory Papillomatosis with Key Opinion Leader PR Newswire PLYMOUTH MEETING, Pa., Jan. 22, 2024 Fireside Chat, moderated by Hartaj Singh of Oppenheimer & Co., will be held on Wednesday, January 24, 2024, at 12:00pm ET PLYMOUTH... More...>>
01/04/20248:00AMPRNUSINOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi)
INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi) PR Newswire PLYMOUTH MEETING, Pa. and REDWOOD CITY, Calif., Jan. 4, 2024 -  Combination therapy to be evaluated in a Phase 3 trial in patients with locoregionally advanced, high-risk, HPV16/18-positive... More...>>
01/03/20248:00AMPRNUSINOVIO Plans to Submit a BLA for INO-3107 as a Potential Treatment for RRP in Second Half of 2024 Under Accelerated Approval Program
INOVIO Plans to Submit a BLA for INO-3107 as a Potential Treatment for RRP in Second Half of 2024 Under Accelerated Approval Program PR Newswire PLYMOUTH MEETING, Pa., Jan. 3, 2024 Company will request Rolling Submission and Priority Review of its Biological License Application (BLA) by U.S. Food and Drug Administration... More...>>
11/09/20234:05PMPRNUSINOVIO Reports Third Quarter 2023 Financial Results and Operational Highlights
INOVIO Reports Third Quarter 2023 Financial Results and Operational Highlights PR Newswire PLYMOUTH MEETING, Pa., Nov. 9, 2023 Achieved significant progress with lead product candidate, INO-3107        Received Breakthrough Therapy designation from U.S. Food and Drug Administration (FDA) as a potential treatment... More...>>
11/01/20238:00AMPRNUSINOVIO Reports Inducement Grants Under Inducement Plan
INOVIO Reports Inducement Grants Under Inducement Plan PR Newswire PLYMOUTH MEETING, Pa., Nov. 1, 2023 PLYMOUTH MEETING, Pa., Nov. 1, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases... More...>>
10/26/20238:00AMPRNUSINOVIO to Report Third Quarter 2023 Financial Results on November 9, 2023
INOVIO to Report Third Quarter 2023 Financial Results on November 9, 2023 PR Newswire PLYMOUTH MEETING, Pa., Oct. 26, 2023 PLYMOUTH MEETING, Pa., Oct. 26, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated... More...>>
10/10/202310:51AMDJNInovio Shares Rise 8% After FDA Feedback for INO-3107
By Chris Wack Inovio shares were up 8% to 39 cents after the company received feedback from the U.S. Food and Drug Administration that data from its completed Phase 1/2 trial of INO-3107 for the treatment of recurrent respiratory papillomatosis could support Inovio's submission of a biological license application... More...>>
10/10/20238:00AMPRNUSINOVIO Receives FDA Feedback that Data from Completed Phase 1/2 Trial of INO-3107 Can Be Used to Submit a BLA Under Accelerated Approval Program
INOVIO Receives FDA Feedback that Data from Completed Phase 1/2 Trial of INO-3107 Can Be Used to Submit a BLA Under Accelerated Approval Program PR Newswire PLYMOUTH MEETING, Pa., Oct. 10, 2023 Previously planned Phase 3 trial no longer required to support Biological License Application (BLA) submission If approved, INO-3107... More...>>
09/27/20237:39PMPRNUSGeneos Therapeutics Closes its Series A3 Financing With Investment of $5 Million
Geneos Therapeutics Closes its Series A3 Financing With Investment of $5 Million PR Newswire PLYMOUTH MEETING, Pa., Sept. 27, 2023 -- Proceeds Will Fund Completion of GT-30 Trial of Personalized Therapeutic Cancer Vaccine in Liver Cancer -- -- Shanghai-based SHC Added to Geneos' Investor Syndicate -- PLYMOUTH MEETING... More...>>
09/07/20238:00AMPRNUSINOVIO Announces U.S. FDA Breakthrough Therapy Designation Granted for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis
INOVIO Announces U.S. FDA Breakthrough Therapy Designation Granted for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis PR Newswire PLYMOUTH MEETING, Pa., Sept. 7, 2023 • Designation based on clinical evidence indicating INO-3107 may demonstrate substantial improvement over existing therapies • First... More...>>
08/29/20238:00AMPRNUSINOVIO to Present at the H.C. Wainwright 25th Annual Global Investment Conference
INOVIO to Present at the H.C. Wainwright 25th Annual Global Investment Conference PR Newswire PLYMOUTH MEETING, Pa., Aug. 29, 2023 PLYMOUTH MEETING, Pa., Aug. 29, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from... More...>>
08/09/20234:05PMPRNUSINOVIO Announces Second Quarter 2023 Financial Results and Provides Strategic Update
INOVIO Announces Second Quarter 2023 Financial Results and Provides Strategic Update PR Newswire PLYMOUTH MEETING, Pa., Aug. 9, 2023 Preparing to initiate pivotal Phase 3 trial of INO-3107 in adult RRP patients in first quarter of 2024; INO-3107 received Orphan Drug Designation from European Commission in second quarter... More...>>